Jack A Syage1, Joseph A Murray2, Peter H R Green3, Chaitan Khosla4. 1. ImmunogenX, 1600 Dove Street, Suite 330, Newport Beach, CA, 92660, USA. 2. Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA. murray.joseph@mayo.edu. 3. Celiac Disease Center at Columbia University, 180 Fort Washington Avenue - HP 934, New York, NY, 10032, USA. 4. Departments of Chemical Engineering and Chemistry, Stanford University, Shriram Center, Room 269, Stanford, CA, 94305-5080, USA.
Abstract
BACKGROUND AND AIMS: Celiac disease (CD) is a widespread condition triggered by dietary gluten and treated with a lifelong gluten-free diet (GFD); however, inadvertent exposure to gluten can result in episodic symptoms. A previous trial of latiglutenase (clinicaltrials.gov; NCT01917630), an orally administered mixture of two recombinant gluten-specific proteases, was undertaken in symptomatic subjects with persistent injury. The primary endpoint for histologic improvement was not met, presumably due to a trial effect. In this post hoc analysis, we investigated the efficacy of latiglutenase for reducing symptoms in subgroups of the study participants based on their seropositivity. METHODS: The study involved symptomatic CD patients following a GFD for at least one year prior to randomization. Patients were treated for 12 weeks with latiglutenase or placebo. Of 398 completed patients, 173 (43%) were seropositive at baseline. Symptoms were recorded daily, and weekly symptom scores were compiled. p values were calculated by analysis of covariance. RESULTS: A statistically significant, dose-dependent reduction was detected in the severity and frequency of symptoms in seropositive but not seronegative patients. The severity of abdominal pain and bloating was reduced by 58 and 44%, respectively, in the cohort receiving the highest latiglutenase dose (900 mg, n = 14) relative to placebo (n = 54). Symptom improvement increased from week 6 to week 12. There was also a trend toward greater symptom improvement with greater baseline symptom severity. CONCLUSIONS:Seropositive CD patients show symptomatic improvement from latiglutenase taken with meals and would benefit from the availability of this treatment.
RCT Entities:
BACKGROUND AND AIMS: Celiac disease (CD) is a widespread condition triggered by dietary gluten and treated with a lifelong gluten-free diet (GFD); however, inadvertent exposure to gluten can result in episodic symptoms. A previous trial of latiglutenase (clinicaltrials.gov; NCT01917630), an orally administered mixture of two recombinant gluten-specific proteases, was undertaken in symptomatic subjects with persistent injury. The primary endpoint for histologic improvement was not met, presumably due to a trial effect. In this post hoc analysis, we investigated the efficacy of latiglutenase for reducing symptoms in subgroups of the study participants based on their seropositivity. METHODS: The study involved symptomatic CDpatients following a GFD for at least one year prior to randomization. Patients were treated for 12 weeks with latiglutenase or placebo. Of 398 completed patients, 173 (43%) were seropositive at baseline. Symptoms were recorded daily, and weekly symptom scores were compiled. p values were calculated by analysis of covariance. RESULTS: A statistically significant, dose-dependent reduction was detected in the severity and frequency of symptoms in seropositive but not seronegative patients. The severity of abdominal pain and bloating was reduced by 58 and 44%, respectively, in the cohort receiving the highest latiglutenase dose (900 mg, n = 14) relative to placebo (n = 54). Symptom improvement increased from week 6 to week 12. There was also a trend toward greater symptom improvement with greater baseline symptom severity. CONCLUSIONS: Seropositive CDpatients show symptomatic improvement from latiglutenase taken with meals and would benefit from the availability of this treatment.
Authors: Daniel A Leffler; Sarah Acaster; Katy Gallop; Melinda Dennis; Ciarán P Kelly; Daniel C Adelman Journal: Value Health Date: 2017-02-14 Impact factor: 5.725
Authors: Daniel Leffler; Sonia S Kupfer; Benjamin Lebwohl; Kevin Bugin; Donna Griebel; Julia Tait Lathrop; Jessica J Lee; Andrew E Mulberg; Elektra Papadopoulos; Juli Tomaino; Sheila E Crowe Journal: Gastroenterology Date: 2016-07-25 Impact factor: 22.682
Authors: Daniel A Leffler; Ciaran P Kelly; Peter H R Green; Richard N Fedorak; Anthony DiMarino; Wendy Perrow; Henrik Rasmussen; Chao Wang; Premysl Bercik; Natalie M Bachir; Joseph A Murray Journal: Gastroenterology Date: 2015-02-13 Impact factor: 22.682
Authors: Pieter Hindryckx; Barrett G Levesque; Tom Holvoet; Serina Durand; Ceen-Ming Tang; Claire Parker; Reena Khanna; Lisa M Shackelton; Geert D'Haens; William J Sandborn; Brian G Feagan; Benjamin Lebwohl; Daniel A Leffler; Vipul Jairath Journal: Gut Date: 2016-10-31 Impact factor: 23.059
Authors: Daniel A Leffler; Melinda Dennis; Brian Hyett; Eoin Kelly; Detlef Schuppan; Ciaran P Kelly Journal: Clin Gastroenterol Hepatol Date: 2007-03-26 Impact factor: 11.382
Authors: Joseph A Murray; Ciarán P Kelly; Peter H R Green; Annette Marcantonio; Tsung-Teh Wu; Markku Mäki; Daniel C Adelman Journal: Gastroenterology Date: 2016-11-15 Impact factor: 22.682
Authors: Charles P Moehs; William J Austill; Aaron Holm; Tao A G Large; Dayna Loeffler; Jessica Mullenberg; Patrick S Schnable; Wayne Skinner; Jos van Boxtel; Liying Wu; Cate McGuire Journal: Plant Physiol Date: 2019-01-29 Impact factor: 8.340
Authors: Elena A Dvoryakova; Maria A Klimova; Tatiana R Simonyan; Ivan A Dombrovsky; Marina V Serebryakova; Valeriia F Tereshchenkova; Yakov E Dunaevsky; Mikhail A Belozersky; Irina Y Filippova; Elena N Elpidina Journal: Int J Mol Sci Date: 2022-06-23 Impact factor: 6.208
Authors: Laura Kivelä; Alberto Caminero; Daniel A Leffler; Maria Ines Pinto-Sanchez; Jason A Tye-Din; Katri Lindfors Journal: Nat Rev Gastroenterol Hepatol Date: 2020-11-20 Impact factor: 46.802
Authors: Jack A Syage; Peter H R Green; Chaitan Khosla; Daniel C Adelman; Jennifer A Sealey-Voyksner; Joseph A Murray Journal: GastroHep Date: 2019-10-08